Immunome Future Growth
Future criteria checks 2/6
Immunome's earnings are forecast to decline at 3.5% per annum while its annual revenue is expected to grow at 55.5% per year. EPS is expected to grow by 19.8% per annum.
Key information
-3.5%
Earnings growth rate
19.8%
EPS growth rate
Biotechs earnings growth | 21.2% |
Revenue growth rate | 55.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Immunome: Why It Has Doubled Over The Last Month
Jan 18Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?
Mar 17Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?
Nov 20Immunome GAAP EPS of -$0.74
Aug 05Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation
Aug 05Immunome gains 34% after preclinical data on COVID-19 antibody
Jun 30We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth
Feb 21Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth
Oct 02Immunome launches $27M private placement
Apr 26Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?
Mar 12Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares
Jan 18Immunome EPS misses by $7.22
Nov 17Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 15 | -193 | -56 | -188 | 4 |
12/31/2025 | N/A | -149 | -40 | -140 | 4 |
12/31/2024 | 8 | -114 | -35 | -129 | 4 |
12/31/2023 | 14 | -107 | -8 | -8 | N/A |
9/30/2023 | 10 | -22 | 3 | 3 | N/A |
6/30/2023 | 7 | -27 | 4 | 4 | N/A |
3/31/2023 | 2 | -30 | 2 | 2 | N/A |
12/31/2022 | N/A | -38 | -29 | -29 | N/A |
9/30/2022 | N/A | -38 | -29 | -29 | N/A |
6/30/2022 | N/A | -36 | -26 | -25 | N/A |
3/31/2022 | N/A | -32 | -21 | -21 | N/A |
12/31/2021 | N/A | -25 | -18 | -18 | N/A |
9/30/2021 | N/A | -21 | -18 | -17 | N/A |
6/30/2021 | N/A | -22 | -16 | -16 | N/A |
3/31/2021 | N/A | -19 | -14 | -14 | N/A |
12/31/2020 | N/A | -18 | -13 | -12 | N/A |
9/30/2020 | N/A | -17 | -9 | -9 | N/A |
6/30/2020 | N/A | -11 | -9 | -8 | N/A |
3/31/2020 | N/A | -11 | -10 | -9 | N/A |
12/31/2019 | N/A | -10 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMNM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMNM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMNM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMNM's revenue (55.5% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: IMNM's revenue (55.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMNM's Return on Equity is forecast to be high in 3 years time